Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles.
We developed a novel magnetic resonance (MR) imaging contrast agent, MAb-magnetite, that was prepared by covalently linking polyethylene glycol-coated magnetite to a monoclonal antibody specific for a human glioma cell-surface antigen. When MAb-magnetite was injected intravenously into tumor-bearing nude mice at a dose of 100 mumol Fe/kg body weight, a 50% decrease in the T2 signal intensity of the tumor was observed, immediately following administration and continued for 48 h. Microscopic observation of the tumor tissue demonstrated localization of MAb-magnetite in cancer cells. These results suggest that MAb-magnetite is a promising agent for MR imaging of neoplasms.
Suzuki
M
M
Department of Biotechnology, School of Engineering, Nagoya University.
Honda
H
H
Kobayashi
T
T
Wakabayashi
T
T
Yoshida
J
J
Takahashi
M
M
D000818:Animals; D000911:Antibodies, Monoclonal; D003287:Contrast Media; D052203:Ferrosoferric Oxide; D005910:Glioma / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D007501:Iron; D008279:Magnetic Resonance Imaging; D051379:Mice; D008819:Mice, Nude; D010087:Oxides; D051381:Rats; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D003287:Contrast Media; D010087:Oxides; D007501:Iron; D052203:Ferrosoferric Oxide